PTO/SB/21 (09-04) Approved for use through 07/31/2006, OMR 0851-0031

Under the Paperwork Reduction Act of 1995	no pareone are required	U.S.	Patent and 1	rademark Office	U.S. DEPARTMENT OF COMMERCE	
	Patent Nu	mber	7,125,975	t displays a valid OWB control number.		
TRANSMITTAL	Issue Date	,	10/24/2006			
FORM	First Name	ed Inventor	Muthiah Manoharan			
(to be used for all correspondence after initial	Title		DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROUPTAKE AND OTHER PROPERTIES			
Total Number of Pages in This Submission	Attenney	Attorney Docket Number ISIS-5425				
	ENCLOSURES	(Check all	that apply)		
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandomment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Parts Uniong 37 CFR 1,52 or 1,53	Change of Co	onvert to a pplication orney, Revocatio orrespondence a claimer	Address	Appe of Appe (Appe (Appe State	Allowance Communication to TC and Communication to Board peals and Interferences at Communication to TC and Hotelog. Bert Reply Brief) interpretation to TC and Hotelog. Bert Reply Brief (TC and Brief) in TC and	
Firm Name	URE OF APPLIC	ANT, ATTO	KNEY, C	K AGENT		
Isis Pharmaceuticals, Inc.	all					
Signature	//	==>				
Printed name Herb Boswell						
Date ////3 / 2 0	16	F	Reg. No.	27,311		
CE I hereby certify that this correspondence is be sufficient postage as first class mail in an envite date shown below:	RTIFICATE OF T	ed to the USPT	O or depos	ited with the U	nited States Postal Service with Alexandria, VA 22313-1450 on	
Signature						
Typed or printed name				Date		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or train a benefit by the public which is to file (and by the USPTO to process) an application. Confederability is governed by 53 U.S.C., 122 and 51 CFR 1.1 and 1.4. This collection is estimated to 2 hours to complete, including pathering, preparing, and submitting the completed application form to the USPTO. The wife of the control of the USPTO is the submitted of the Confederability of the Confederabilit

Under the Peperwork Reduction Act of 1995, no persons ere required to respond to a collection of information unless it displays a veilid OMB control numb (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page _ 1 _ of _ 5

PATENT NO. : 7.125.975 APPLICATION NO.: 10/755,166

ISSUE DATE : 10/24/2006

INVENTOR(S) : Muthiah Manoharan, et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

1) Title Page:

Item [60], Related U.S. Application Data, please delete

"Continuation of application No. 10/073,718, filed on Feb. 11, 2002, now Pat. No. 6,831,166, which is a division of application No. 09/633,659, filed on Aug. 7, 2000, now Pat. No. 6,395,492, which is a division of application No. 08/211.882, filed on Apr. 22, 1994, now Pat. No. 6.153,737, which is a continuation-inpart of application No. PCT/US92/09196, filed on Oct. 23, 1992 "

and insert therefore

- --Continuation of application No. 10/073,718, filed on Feb. 11, 2002, now Pat. No. 6,831,166, which is a division of application No. 09/633,659, filed on Aug. 7, 2000, now Pat. No. 6,395,492, which is a division of application No. 08/211,882, filed as application No. PCT/US92/09196 on Oct. 23, 1992, now Pat. No. 6.153.737.--:
- 2) Column 6, line 21, please delete "B6" and insert therefore -- B6.--;
- 3) Column 9, line 61, please delete ".";
- 4) Column 10, line 12, please delete "-":
- 5) Column 10, line 54, please delete "Bas" and insert therefore -- Base--;
- 6) Column 11, line 58, please delete "." after "treated";
- 7) Column 12, line 13, please delete "C_sT_sG_s T_sC_sT_s C_sC_sA_s T_sC_sC_s T_sC_sT_s T_sC_sA C_sT" and insert therefore -- C₈T₈G₈ T₈C₈T₈ C₈C₈A₈ T₈C₈C₈ T₈C₈T₈ T₈C₈A₈ C₈T₈-:

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Isis Pharmaceuticals, Inc.

1896 Rutherford Rd.

Carlsbad, CA 92008

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Peperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number. (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 2 of 5

: 7,125,975 APPLICATION NO.: 10/755,166 ISSUE DATE : 10/24/2006

PATENT NO.

INVENTOR(S) : Muthiah Manoharan, et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- 8) Column 15, line 47, please delete "is" and insert therefore -- "s" --:
- 9) Column 17, line 14, please delete "Na2CO3/1M" and insert therefore --Na2CO3/1M--;
- 10) Column 17, line 44, please delete "Na2HCO3/1M" and insert therefore --Na2HCO3/1M--;
- 11) Column 19, please delete

TABLE 1

HPLC Retention Times Of Oligonucleotides Functionalized At 2' Position

	Retention Time Minutes				
Oligomer	Mono Substitution	Multiple Substitution			
Oligomer 12 ¹	21.78				
Oligomer 131	22.50				
Oligomer 19 ²	23.58				
Oligomer 20 ²	24.16 ^a	25.19 ^b			
Oligomer 213	26.65				
Oligomer 223	26.99 ^a	29.33 ^b			
-	27.55 ^a				
Oligomer 234	30.10				
Oligomer 24 ⁴	30.38 ^a	37.00 ^b			
•	32.22ª				
Oligomer 25 ⁵ Oligomer 26 ⁵	28.06				
Oligomer 265	28.14 ^a	33.32 ^b			
•	29.24 ^a	-0.02			

MAILING ADDRESS OF SENDER (Please do not use customer number below):

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Officer, U.S. Department of Commence, P.O. Box 1499, Alexandria, V.A. 22313-1499, D.D NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1459, Alexandria, VA 22313-1450.

Isis Pharmaceuticals, Inc.

¹⁸⁹⁶ Rutherford Rd.

Carlsbad, CA 92008

Page 3 of 5

U.S. Patent and Trademark Office; U.S. P

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 7,125,975

APPLICATION NO.: 10/755,166

ISSUE DATE : 10/24/2006

INVENTOR(S) : Muthiah Manoharan, et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

and insert therefore

TABLE 1

HPLC Retention Times Of Oligonucleotides Functionalized
At 2' Position

		Retention Time Minutes			
Oligomer	Mono Substitution	Multiple Substitution			
Oligomer 12 ¹	21.78				
Oligomer 13 ¹		22.50			
Oligomer 19 ²	23.58				
Oligomer 20 ²		24.16 ^a 25.19 ^b			
Oligomer 213	26.65				
Oligomer 22 ³		26.99 ^a 29.33 ^b			
•		27.55°			
Oligomer 23⁴	30.10				
Oligomer 24 ⁴		30.38 ^a 37.00 ^b			
		32.22 ^e			
Oligomer 25 ⁵	28.06				
Oligomer 25 ⁵ Oligomer 26 ⁵		28.14 ^a 33.32 ^b			
•		29.24 ^a			

- 12) Column 21, line 14, please delete "Prot in-Conjugated" and insert therefore -- Protein-Conjugated --;
- 13) Column 21, line 27, please delete ""is" and insert therefore -- "s" --:

MAILING ADDRESS OF SENDER (Please do not use customer number below):

- Isis Pharmaceuticals, Inc.
- 1896 Rutherford Rd.
- Carlsbad, CA 92008

This collection of Information is required by 37 CFR 1.322, 1.323, and 1.324. The Information is required to obtain or retain a benefit by the public which is to fix and by the USFPTO to process an exploration. Confidentially is governed by \$5 U.S. C. 122 and \$7 CFR 1.14. This Collection is estimated to 1 hour to complete, including gathering, preparing, and submitting the completed application form to the USFTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete is from any collection form to the USFTO. The will vary depending upon the Individual case. Any comments on the amount of time you require to complete its form and/or suggestors for reducing the burden, should be sent to the Child Test formation. Officer, U.S. Department of Commence. P.O. Box 1450, Alexandria, VA. 22313-1460. DO NOT SERO FEES OR COMPLETED.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page __4__ of __5

PATENT NO. : 7.125.975 APPLICATION NO.: 10/755.166

ISSUE DATE : 10/24/2006

INVENTOR(S) : Muthiah Manoharan, et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

14) Column 22, please delete

TABLE 2

OLIGONUCLEOTIDE ANALYSIS VIA ENZYMATIC DIGESTION

Oligomer	Observed Ratios					
	Abs. max.	267	252	267	260	
	С	G	Т	A [*]	Α	
Oligomer 10	2	1		1		
Oligomer 11	3	5	2	1		
Oligomer 12	9	1	8	1	1	
Oligomer 13	9	1	8	2		

And insert therefore

TABLE 2

OLIGONUCLEOTIDE ANALYSIS VIA ENZYMATIC DIGESTION

Observed Ratios							
Oligomer	Abs. max.	267	252	267	260		
		С	G	T	A.	Α	
Oligomer 10		2	1		1		
Oligomer 11		3	5	2	1		
Oligomer 12		9	1	8	1	1	
Oligomer 13		9	1	8	2		;

15) Column 24, line 46, please delete "phase-HPLC" and insert therefore --phase HPLC--;

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Isis Pharmaceuticals, Inc.

1896 Rutherford Rd.

Carlsbad, CA 92008

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Petent end Trademerk Office; U.S. DEPARTMENT OF COMMERCE Under the Peperwork Reduction Act of 1995, no persons ere required to respond to e collection of information unless it displeys a valid OMB control number. (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page _ 5 _ of _ 5

PATENT NO. : 7.125.975 APPLICATION NO.: 10/755,166

ISSUE DATE : 10/24/2006

INVENTOR(S) : Muthiah Manoharan, et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

16) Column 29, line 7, please delete "solution-of" and insert therefore --solution of --:

17) Column 39, line 19, please delete "3" and insert therefore -- 30--:

18) Column 46, Claim 5, lines 32-33, please delete "5'-position" and insert therefore --5'-O-position--.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Isis Pharmaceuticals, Inc.

1896 Rutherford Rd. Carlsbad, CA 92008

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application, Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.